Currency values in € and $ are approximate. A site license covers all report users located at a single geographical address. Google Checkout is only available for single purchases.
| Report (View Catalogue) | Site License | Global License |
|---|---|---|
| Antibiotics and Drug Resistance: New drug innovation and the strategy to combat antibiotic resistance mechanisms (January 2008, PDF). | $5,400 / €3,800 / £3,000 |
$8,900 / €6,300 / £5,000 |
| Apoptosis: Programmed cell death as an emerging therapeutic opportunity (October 2008). | ||
| Cancer Drug Resistance: Resistance Mechanisms, Resistance Biomarkers, Current & Pipeline Cancer Drugs and Strategies (September 2008, PDF). | $6,000 / €4,225 / £3,350 |
$8,900 / €6,300 / £4,995 |
| Cancer Stem Cells: Emerging Therapeutic, Diagnostic and Market Opportunities (June 2008, PDF). | $5,700 / €4,000 / £3,200 | $8,900 / €6,300 / £5,000 |
| Dyslipidemia: Opportunities in Cardiovascular Risk Reduction (August 2008, PDF + CHM). | $5,400 / €3,800 / £3,000 |
$8,900 / €6,300 / £5,000 |
| Peripheral Neuropathy and Neuropathic Pain: Current, pipeline and emerging drugs for the treatment of peripheral neuropathy and neuropathic pain (January 2008, PDF). | $5,400 / €3,800 / £3,000 |
$8,000 / €5,700 / £4,500 |
| Notes: Currency values in € and $ are approximate. A site license covers all report users located at a single geographical address. Google Checkout is only available for single purchases.
|
||
Copyright © Biophoenix Limited (2008)